Jong-Ho Park

Dr. Jong-Ho Park

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2011 in Journal of Ginseng Research
Verified
Journal Article
Open access
YKYong-Seong Kim
Yong-Seong Kim
YKYong-Hoon Kim
Yong-Hoon Kim
JNJung-Ran Noh
Jung-Ran Noh
ECEun-Sang Cho
Eun-Sang Cho
JPJong-Ho Park
Jong-Ho Park
HSHwa-Young Son
Hwa-Young Son
Korean red ginseng (KRG), the steamed root of Panax ginseng Meyer, has a variety of biological properties, including anti-inflammatory, antioxidant and anticancer effects. Aflatoxin B1 (AFB1) produced by the Aspergillus spp. causes acute hepatotoxicity by lipid peroxidation and oxidative DNA damage, and induces liver carcinoma in humans and laboratory animals. This study was performed to examine the protective effects of KRG against hepatotoxicity induced by AFB1 using liver-specific serum marker analysis, histopathology, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling. In addition, to elucidate the possible mechanism of hepatoprotective effects, superoxide dismutase, catalase, glutathione peroxidase, and malondialdehyde were analyzed. Rats were treated with 250 mg/kg of KRG (KRG group) or saline (AFB1 group) for 4 weeks and then received 150 μg/kg of AFB1 intraperitoneally for 3 days. Rats were sacrificed at 12 h, 24 h, 48 h, 72 h, or 1 wk after AFB1 treatment. In the KRG pre-treatment group, serum alanine aminotransferase, aspartate aminotransferase, and malondialdehyde levels were low, but superoxide dismutase, catalase, and glutathione peroxidase activities were high as compared to the AFB1 alone group. Histopathologically, AFB1 treatment induced necrosis and apoptosis in hepatocytes, and led to inflammatory cells infiltration in the liver. KRG pre-treatment ameliorated these changes. These results indicate that KRG may have protective effects against hepatotoxicity induced by AFB1 that involve the antioxidant properties of KRG.

7 December 2023 in Cancers
Verified
Journal Article
Open access
PDF file
HJHye-Ji Jung
Hye-Ji Jung
JPJong-Ho Park
Jong-Ho Park
JOJINA OH
JINA OH
SLSae-Mi Lee
Sae-Mi Lee
IJIl-Yeo Jang
Il-Yeo Jang
HCHyun Jin Choi
Hyun Jin Choi
Purpose: Antibiotic use preceding immune checkpoint inhibitor (ICI) treatment has been associated with a decreased efficacy of ICI in solid tumors. In this study, we evaluated the effect of antibiotic use before ICI therapy on oncological outcomes. Methods: We examined patients with recurrent gynecologic malignancies at two academic institutions. The clinical data, including antibiotic use within 60 days of ICI initiation, type of antibiotics, reasons for antibiotic use, body mass index, tumor site, chemotherapy-free interval, prior history of radiotherapy, disease control rate (DCR), and overall survival (OS), were assessed. Results: Of 215 patients, 22.9% (n = 47) received antibiotics before ICI treatment. The most common cancer was ovarian (52.1%, n = 112), followed by cervical (24.7%, n = 53) and endometrial (16.7%, n = 36). When we divided the cohort based on antibiotic use before ICIs, there were no significant differences in the DCR and baseline characteristics between the two groups. On multivariate analyses, the variables associated with poor OS were previous use of antibiotics for a cumulative duration of >14 days (HR 2.286, 95% CI 1.210–4.318; p = 0.011); Eastern Cooperative Oncology Group 2 or 3 (HR 4.677, 95% CI 2.497–8.762; p < 0.001); and chemotherapy-free interval of 14 days was associated with reduced survival in recurrent gynecologic malignancies.

31 July 2022 in Cardiovascular Prevention and Pharmacotherapy
Verified
Journal Article
Open access
TPTaegyun Park
Taegyun Park
KHKyungdo Han
Kyungdo Han
DSDongwook Shin
Dongwook Shin
JPJong-Ho Park
Jong-Ho Park
Background: Dyslipidemia is common in patients with type 2 diabetes mellitus (T2D) and contributes to an increased risk of cardiovascular disease. Previous studies have shown that treatment with thiazolidinediones (TZDs) and sodium-glucose cotransporter-2 inhibitors (SGLT2-i) may help to improve dyslipidemia in T2D patients. In this study, we investigated whether patients treated with TZD and SGLT2-i showed greater improvement in high-density lipoprotein cholesterol (HDL-C) levels than those treated with only SGLT2-i.Methods: From the National Health Insurance Service database of Korea, we extracted all patients who first received SGTL2-i from 2014 to 2016. Propensity score matching was performed to balance the two groups: group A (SGTL2-i and TZD, regardless of other antidiabetic medications) and group B (SGTL2-i only without TZD, regardless of other antidiabetic medications). Posttreatment HDL-C levels were compared by the Student t-test.Results: In total, 1,400 T2D patients (700 in each group) were matched by propensity score matching. There was a significant posttreatment increase in HDL-C in group A (49.54±20.03 to 51.6±12.92 mg/dL, P=0.007), but not in group B (49.14±13.52 to 49.1±2.15 mg/dL, P=0.937). Group A also showed significantly higher posttreatment HDL-C levels than group B (51.4±12.92 vs. 49.1±12.15 mg/dL, P<0.001). Regarding the secondary endpoints, posttreatment triglyceride levels were lower (P<0.001), but total cholesterol (P=0.131) and low-density lipoprotein cholesterol levels (P=0.054) were not different after treatment.Conclusions: The combination of SGTL2-i and TZD may be more effective in ameliorating dyslipidemia in T2D patients than SGLT2-i alone. However, further studies are needed to confirm this finding.

30 June 2013 in Korean Journal of Veterinary Science
Verified
Journal Article
Closed access
JPJong-Ho Park
Jong-Ho Park
ECEun-Sang Cho
Eun-Sang Cho
SRSi-Yun Ryu
Si-Yun Ryu
JJJu-Young Jung
Ju-Young Jung
HSHwa-Young Son
Hwa-Young Son

27 August 2025 in medRxiv
Verified
Preprint
Open access
PDF file
JPJong-Ho Park
Jong-Ho Park
TPTae Gyun Park
Tae Gyun Park
HCHyun Jin Choi
Hyun Jin Choi
Introduction: Anemia, particularly iron deficiency anemia, is prevalent among reproductive-aged women and often linked to benign gynecologic disorders such as leiomyoma and adenomyosis. While anemia is a recognized contributor to hemodynamic stress, its role as an independent cardiovascular risk factor in young women remains underexplored. Methods: We conducted a nationwide retrospective cohort study using Korean National Health Insurance Service data (2011–2023) including 1,706,288 premenopausal women aged 20–53 years with benign uterine disorders and no prior cardiovascular or cerebrovascular disease. Anemia was defined by ICD-10 code D50. Propensity score matching (1:1) was applied to balance cardiovascular risk factors. Outcomes included hypertension, ischemic heart disease (IHD), heart failure (HF), and cerebrovascular disease (CVD). Relative risks (RRs) were estimated overall and stratified by age group and uterine pathology. Results: After matching, 627,451 women were included in each group. Anemia was associated with higher risks of hypertension (RR 1.35; 95% CI 1.34–1.37), IHD (RR 1.44; 95% CI 1.42–1.46), HF (RR 1.45; 95% CI 1.43–1.47), and CVD (RR 1.26; 95% CI 1.25–1.28). The relative risk was highest among women aged 20–29 years for hypertension (RR 1.68; 95% CI 1.41–2.02) and CVD (RR 1.45; 95% CI 1.22–1.72). Coexisting uterine leiomyoma conferred the greatest vascular risk across all outcomes. Conclusions: Anemia is an independent risk factor for early-onset cardiovascular and cerebrovascular disease in women with benign uterine disorders, particularly those younger than 40 years. Incorporating gynecologic assessment into cardiovascular risk screening may enhance early prevention strategies in this population.